alpha-(3-aminopropyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile: N-demethylated analog of verapamil [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 161569 |
| SCHEMBL ID | 2456966 |
| MeSH ID | M0067238 |
| Synonym |
|---|
| 5-amino-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile |
| d 620 |
| 27487-66-7 |
| 5-amino-2-(3,4-dimethoxyphenyl)-2-propan-2-ylpentanenitrile |
| alpha-(3-aminopropyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile |
| d-620 |
| 1ht7nt1n2o , |
| unii-1ht7nt1n2o |
| SCHEMBL2456966 |
| 5-amino-2-(3,4-dimethoxyphenyl)-2-isopropylpentanenitrile # |
| UCWOSFAANAZHKR-UHFFFAOYSA-N |
| benzeneacetonitrile, .alpha.-(3-aminopropyl)-3,4-dimethoxy-.alpha.-(1-methylethyl)- |
| 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexylamine |
| d-620, (+/-)- |
| 1-isopropyl-1-propylamino-(3,4-dimethoxyphenyl)acetonitrile |
| (2rs)-5-amino-2-(3,4-dimethoxyphenyl)-2-isopropylpentanenitrile |
| AKOS030228470 |
| 5-amino-2-(3,4-dimethoxyphenyl)-2-isopropylpentanenitrile |
| Q27252431 |
| DTXSID10893324 |
| 5-amino-2-(3,4-dimethoxyphenyl)-2-(2-propanyl)pentanenitrile |
| SB81554 |
| 5-amino-2-(3,4-dimethoxyphenyl)-2-(propan-2-yl)pentanenitrile |
alpha-(3-aminopropyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile is involved in 1 pathway(s), involving a total of 7 unique proteins and 6 unique compounds
| Pathway | Proteins | Compounds |
|---|---|---|
| Verapamil Pathway, Pharmacokinetics | 7 | 6 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (50.00) | 18.7374 |
| 1990's | 4 (40.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Article | Year |
|---|---|
| [information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | |
| Article | Year |
|---|---|
| Plasma levels and urinary excretion of verapamil, norverapamil, N-dealkylverapamil (D617), N-dealkylnorverapamil (D620) following oral administration of a slow-release preparation. International journal of clinical pharmacology research, Volume: 5, Issue: 2 | 1985 |
| Disposition kinetics and urinary excretion of verapamil and some of its primary metabolites after oral administration in patients with angina pectoris. International journal of clinical pharmacology, therapy, and toxicology, Volume: 24, Issue: 1 | 1986 |
| [information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | |
| Article | Year |
|---|---|
| Influence of metabolites on protein binding of verapamil enantiomers. British journal of clinical pharmacology, Volume: 39, Issue: 5 | 1995 |
| Requirements for drug monitoring of verapamil: experience from an unselected group of patients with cardiovascular disease. Pharmacology & toxicology, Volume: 66, Issue: 3 | 1990 |
| Electrophysiologic effects of verapamil metabolites in the isolated heart. Journal of cardiovascular pharmacology, Volume: 17, Issue: 5 | 1991 |
| [information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | |